Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference152 articles.
1. Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018;35:1295–332.
2. Moots R, Azevedo V, Coindreau JL, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19:37.
3. McKinnon RA, Cook M, Liauw W, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. Biodrugs. 2018;32:27–52.
4. Yifei L, Skup M, Yang M, Qi C, Doctor T. Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies [abstract P445]. J Crohns Colitis. 2019;13:S334.
5. Reiland J-B, Freischem B, Roediger A. What pricing and reimbursement policies to use for off-patent biologicals in Europe? Results from the second EBE biological medicines policy survey. GaBI J. 2017;6:1–18.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献